Chitosan-folate coated mesoporous silica nanoparticles as a smart and pH-sensitive system for curcumin delivery

Abstract

Biocompatible pH and folate sensitive large pore MSNs with controllable and targeted CUR delivery.

Poly-l-lactic acid scaffold incorporated chitosan-coated mesoporous silica nanoparticles as pH-sensitive composite for enhanced osteogenic differentiation of human adipose tissue stem cells by dexamethasone delivery

“…As shown in XRD pattern (Figure 1(B)), the presence of CS on the surface of MSN could preserve a slight decrease in the intensity in comparison with MSN. The results are in accordance with published reports [29,31,33] and confirmed the formation of hexagonal structure of MSN.…”

“…MSNs were prepared in the presence of mesitylene based on previous procedures [32,33]. Briefly, 7.0 ml of mesitylene, as a swelling agent of micelles, and 1.0 g of CTAB were added to a solution containing 480 ml of deionized water and 3.5 ml of NaOH (2 M).…”

“…Dexa was loaded into the MSN according to reported procedures with some modifications [33,34]. Briefly, 50 mg MSN was added into 5 ml Dexa solution in distilled water at a concentration of 2 mg/ml.…”

Etoposide encased folic acid adorned mesoporous silica nanoparticles as potent nanovehicles for enhanced prostate cancer therapy: synthesis, characterization, cellular uptake and biodistribution

“…Haem compatibility of MSNs was adjudged by Haemolysis assay [22,23]. Triton X-100 treated RBCs were taken as a positive control with greatest lysis being observed and RBCs in PBS 7.4 were taken as negative control with unmistakably no lysis discovered.…”

Biomedical applications of mesoporous silica particles

“…However, another study of two differently-ordered pore structures, MCM-41 and MCM-48, showed that the cubic pore structure of the MCM-48 decreased the release rate, likely due to the longer mean free path of a drug molecule through the particle to reach the bulk solution Fickian diffusion and Case II transport, respectively [75]. However, the term fit values for MCM-41 and WO are smaller than the 0.43 lower bound, a result often seen in drug delivery studies using sub-100 nm particles [21,24,78]. In a study of particle size distribution on the kinetics of drug release [79], Ritger and Peppas found that variation in particle sizes resulted in accelerated drug release at early time points due to diffusion from particles smaller than the mean size and delayed release at later time points due to diffusion from particles larger than the mean size.…”